We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cangene Awarded Biodefence Contract for AIGIV


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cangene Awarded Biodefence Contract for AIGIV"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Cangene Corporation (Cangene) has announced that it has been awarded a multiple award indefinite delivery/indefinite quantity contract to potentially provide its Anthrax Immune Globulin Intravenous (AIGIV) to the U.S. Department of Health and Human Services (HHS) for the U.S. government's biodefence program.

Cangene's AIGIV, a hyperimmune antibody product specific for Bacillus anthracis bacteria, was first accepted into the U.S. Strategic National Stockpile in 2007.

Under the terms of the five-year contract, Cangene could be awarded delivery orders for the collection and storage of anti-Anthrax human plasma, for the manufacturing of bulk drug substance and AIGIV final drug product.

The contract's work statement has a total potential maximum value of approximately $264 million to Cangene.

In conjunction with the contract award, Cangene was awarded the first task/delivery order under the contract. The order is for the collection and storage of anti-Anthrax human plasma sufficient to manufacture 10,000 doses of bulk drug substance or final drug product.

This order is expected to generate aggregate revenue of approximately $63 million for Cangene for fiscal years 2014, 2015 and 2016, which is included in the aforementioned approximate total potential maximum value of the contract's work statement.

John A. Sedor, President and CEO of Cangene, said: "We are proud to have been selected by the U.S. government for this important medical countermeasure. This marks our second major biodefence contract this year, with the extension of our VIGIV contract with the Centers for Disease Control and Prevention that we announced earlier this month, underscoring our leadership in biodefence. We appreciate our long-standing relationship with the U.S. Department of Health and Human Services, and look forward to continuing to support its critical biodefence preparedness program."

This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201300009I.

Advertisement